Bill Nye is back in his lab with NAF and Biogen—breaking down the science of Friedreich Ataxia in a new video series. WATCH NOW
Drug companies must follow a detailed process to build and submit their New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). You can read more about NDAs in an earlier PrepRARE article here. But did you know that the FDA has its own set of rules to Read More…
If you’ve ever felt overwhelmed trying to understand complex medical research, you’re not alone. That’s why SCAsource was created—to make Ataxia research accessible to everyone. What is SCAsource? SCAsource is a publication where Ataxia researchers write plain-language articles about the latest research studies and scientific discoveries. It’s designed specifically for Read More…
We’re proud to announce that we funded 18 research grants for 2025 totaling $730K! For the funding term of March 1, 2025 – February 28, 2026, NAF received 96 Letters of Intent and 33 grant applications. ~50 scientific reviewers scored full applications, assigning a score between 1.0 and 5.0 (1= outstanding) Read More…
In clinical research, scientists design studies to learn more about diseases and answer questions about new treatment options. Interventional clinical trials are used to better understand the safety and effectiveness of a new drug or medical device. Observational clinical trials help researchers learn more about how diseases develop over time Read More…
NAF Awarded a Record Number of Projects in 2024 18 Studies Funded Totaling $845k Funded! We had our most competitive year ever for Ataxia research grant applications! As a result of the generosity of our donors, NAF was able to fund a record number of Ataxia research grants in 2024! Read More…
Ataxia is complex; the diverse symptoms it presents makes every individual’s experience uniquely challenging. As a person ages, determining whether changes are caused by Ataxia or unrelated causes can be difficult, especially when symptoms impact the way a person thinks and feels. It is important to understand Ataxia’s impact beyond Read More…
It takes a long time to develop a new drug. Not to mention it can be very expensive. But why does it take so long and cost so much? In this article, we will be going through the five key steps in drug development to shed some light on this Read More…
While some begin their careers with a specific specialization – ready to focus on making a difference in a certain field – Dr. Tetsuo Ashizawa’s path to becoming an internationally acclaimed physician scientist specializing in Ataxia was anything but predetermined. Born in Tokyo in 1948, Dr. Tee, as he prefers Read More…
The following is a high-level overview of the Katie Campbell CRC-SCA Face-to-Face Meeting held from September 11-13, 2023, in Bloomington, Minnesota. This meeting focused on logistics and discussion of the ongoing Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA) Natural History Study. Session 1: CRC-SCA Progress and Introductions Read More…
Thank you for submitting your comments for the FDA! Troriluzole, an experimental drug being developed by Biohaven, completed Phase 3 clinical trials last year. While the primary endpoint assessing benefit across all Spinocerebellar Ataxia (SCA) types was not met, Biohaven believes the results show benefit among participants with SCA Type 3 Read More…
